SEARCH

SEARCH BY CITATION

References

  • 1
    Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, Dayton CS et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994;149:450454.
  • 2
    King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164:11711181.
  • 3
    Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994;150:967972.
  • 4
    American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646664.
  • 5
    Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:10841090.
  • 6
    Caminati A, Bianchi A, Cassandro R, Mirenda MR, Harari S. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 2009;103:117123.
  • 7
    Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543548.
  • 8
    Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538542.
  • 9
    Harari S, Caminati A. Idiopathic pulmonary fibrosis. Allergy 2005;60:421435.
  • 10
    Martinez FJ, Flaherty K. Pulmonary function testing in idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006;3:315321.
  • 11
    Gay SE, Kazerooni EA, Toews GB, Lynch JP, Gross BH, Cascade PN et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998;157:10631072.
  • 12
    Caminati A, Harari S. Which prognostic indicator should we use for the clinical practice in the initial evaluation and follow-up of IIP: should we stand on PFT, HRCT or… whatever? Sarcoidosis Vasc Diffuse Lung Dis 2005;22:S24S30.
  • 13
    Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005;128:23932399.
  • 14
    Hunninghake GW, Lynch DA, Galvin JR, Gross BH, Müller N, Schwartz DA et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 2003;124:12151223.
  • 15
    Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001;164:17221727.
  • 16
    Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157:13011315.
  • 17
    King TE Jr, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001;164:10251032.
  • 18
    Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:963996.
  • 19
    King TE Jr, Du Bois RM. Elucidating the causes and examining the latest clinical findings in pulmonary fibrosis. Eur Respir Rev 2008;17:105107.
  • 20
    Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636643.
  • 21
    Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136151.
  • 22
    Gross TG, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517525.
  • 23
    King TE Jr, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G et al. Analyses of efficacy end points in a controlled trial of interferon-gamma 1b for idiopathic pulmonary fibrosis. Chest 2005;127:171177.
  • 24
    Myers JL, Katzenstein AL. Epithelial necrosis and alveolar collapse in the pathogenesis of usual interstitial pneumonia. Chest 1988;94:13091311.
  • 25
    Daniil ZD, Gilchrist FC, Nicholson AG, Hansell DM, Harris J, Colby TV et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999;160:899905.
  • 26
    Fukuda Y, Basset F, Ferrans VJ, Yamanaka M. Significance of early intra-alveolar fibrotic lesions and integrin expression in lung biopsy specimens from patients with idiophatic pulmonary fibrosis. Hum Pathol 1995;26:5361.
  • 27
    Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis: ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991;138:12571265.
  • 28
    Cool CD, Groshong SD, Rai PR, Henson PM, Stewart JS, Brown KK. Fibroblast foci are not discrete sites of lung injury or repair. The fibroblast reticulum. Am J Respir Crit Care Med 2006;174:654658.
  • 29
    Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002;122:286S289S.
  • 30
    Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C et al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 2005;166:675684.
  • 31
    Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 2005;6:56.
  • 32
    Travis WD, Colby TV, Koss MN, Rosado-de-Christenson ML, Müller NL, King TE Jr. Idiopathic interstitial pneumonia and other diffuse parenchymal lung disease. In: Donald West King,  editor. Non-neoplastic disorders of the lower respiratory trac. Washington: American Registry of Pathology and the Armed Forces Institute of Pathology, 2002:5972.
  • 33
    Selman M, Pardo A. The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003;29:93S97S.
  • 34
    Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006;173:188198.
  • 35
    Noble PW. Epithelial fibroblast triggering and interactions in pulmonary fibrosis. Eur Respir Rev 2008;17:123129.
  • 36
    Basset F, Ferrans VJ, Soler P, Takemura T, Fukuda Y, Crystal RG. Intraluminal fibrosis in interstitial lung disorders. Am J Pathol 1986;122:443461.
  • 37
    Chilosi M, Poletti V, Murer B, Lestani M, Cancellieri A, Montagna L et al. Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63. Lab Invest 2002;82:13351345.
  • 38
    Katzenstein AL. Pathogenesis of “fibrosis” in interstitial pneumonia: an electron microscopic study. Hum Pathol 1985;16:10151024.
  • 39
    Kawanami O, Ferrans VJ, Crystal RG. Structure of alveolar epithelial cells in patients with fibrotic lung disorders. Lab Invest 1982;46:3953.
  • 40
    Corrin B, Dewar A, Rodriguez-Roisin R, Turner-Warwick M. Fine structural changes in cryptogenic fibrosing alveolitis and asbestosis. J Pathol 1985;147:107119.
  • 41
    Studer SM, Kaminski N. Towards systems biology of human pulmonary fibrosis. Proc Am Thorac Soc 2007;4:8591.
  • 42
    Antoniades HN, Bravo MA, Avila RE, Galanopoulos T, Neville-Golden J, Maxwell M et al. Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 1990;86:10551064.
  • 43
    Nash JR, McLaughlin PJ, Butcher D, Corrin B. Expression of tumour necrosis factor-alfa in cryptogenic fibrosing alveolitis. Histopathology 1993;22:343347.
  • 44
    Khalil N, O’Connor RN, Unruh HW, Warren PW, Flanders KC, Kemp A et al. Increased production and immunohistochemical localization of transforming growth factor-β in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991;5:155162.
  • 45
    Giaid A, Michel RP, Steward DJ, Sheppard M, Corrin B, Hamid Q. Expression of endothelin-1 in lung of patients with cryptogenic fibrosing alveolitis. Lancet 1993;341:15501554.
  • 46
    Pan LH, Yamauchi K, Uzuki M, Nakanishi T, Takigawa M, Inoue H et al. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J 2001;17:12201227.
  • 47
    Schock F, Perrimon N. Molecular mechanisms of epithelial morphogenesis. Annu Rev Cell Dev Biol 2002;18:463493.
  • 48
    Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131142.
  • 49
    Moustakas A, Heldin CH. Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 2007;98:15121520.
  • 50
    Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005;24:57645774.
  • 51
    Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005;17:548558.
  • 52
    Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006;66:83198326.
  • 53
    Willis BC, Borok Z. TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2007;293:L525L534.
  • 54
    Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, Du Bois RM et al. Induction of epithelial–mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005;166:13211332.
  • 55
    Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006;103:1318013185.
  • 56
    Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLos Med http://www.plosmedicine.org 2008;5:e62.
  • 57
    Koli K, Myllarniemi M, Vuorinen K, Salmenkivi K, Ryynänen MJ, Kinnula VL et al. Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis. Am J Pathol 2006;169:6171.
  • 58
    Warburton D, Schwarz M, Tefft D, Flores-Delgado G, Anderson KD, Cardoso WV. The molecular basis of lung morphogenesis. Mech Dev 2000;92:5581.
  • 59
    Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006;3:364372.
  • 60
    Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:13501358.
  • 61
    Horowitz JC, Thannickal VJ. Idiopathic pulmonary fibrosis: new concepts in pathogenesis and implications for drug therapy. Treat Respir Med 2006;5:325342.
  • 62
    Cantin AM, North SL, Fells GA, Hubbard RC, Crystal RG. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest 1987;79:16651673.
  • 63
    Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000;279:L1005L1028.
  • 64
    Thannickal VJ, Aldweib KD, Fanburg BL. Tyrosine phosphorylation regulates H2O2 production in lung fibroblasts stimulates by transforming growth factor beta1. J Biol Chem 1998;273:2361123615.
  • 65
    Maeyama T, Kuwano K, Kawasaki M, Kunitake R, Hagimoto N, Matsuba T et al. Upregulation of Fas-signalling molecules in lung epithelial cells from patients with idiopathic pulmonary fibrosis. Eur Respir J 2001;17:180189.
  • 66
    Kuwano K, Hagimoto N, Kawasaki M, Yatomi T, Nakamura N, Nagata S et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999;104:1319.
  • 67
    Aoshiba K, Yasui S, Tamaoki J, Nagai A. The Fas/Fas-ligand system is not required for bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2000;162:695700.
  • 68
    Wang R, Zagariya A, Ang E, Ibarra-Sunga O, Uhal BD. Fas-induced apoptosis of alveolar epithelial cells require ANG II generation and receptor interaction. Am J Physiol 1999;277:L1245L1250.
  • 69
    Papp M, Li X, Zhuang J, Wang R, Uhal BD. Angiotensin receptor subtype AT (1) mediates alveolar epithelial cell apoptosis in response to ANG II. Am J Physiol Lung Cell Mol Physiol 2002;282:L713L718.
  • 70
    Uhal BD, Gidea C, Bargout R, Bifero A, Ibarra-Sunga O, Papp M et al. Captopril inhibits apoptosis in human lung epithelial cells: a potential antifibrotic mechanism. Am J Physiol 1998;275:L1013L1017.
  • 71
    Li X, Rayford H, Uhal BD. Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. Am J Pathol 2003;163:25232530.
  • 72
    Otsuka M, Takahashi H, Shiratori M, Chiba H, Abe S. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 2004;59:3138.
  • 73
    Phatak P, Burger AM. Telomerase and its potential for therapeutic intervention. Br J Pharmacol 2007;152:10031011.
  • 74
    Holt SF, Shay JW, Wright WF. Refining the telomere-telomerase hypothesis of aging and cancer. Nat Biotechnol 1996;14:17341741.
  • 75
    Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007;356:13171326.
  • 76
    Morlà M, Busquets X, Pons J, Sauleda J, MacNee W, Agustí AG. Telomere shortening in smokers with and without COPD. Eur Respir J 2006;27:525528.
  • 77
    Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003;200:500503.
  • 78
    Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY et al. Circulating fibrocytes traffic to the lungs in response to CXCL 12 and mediate fibrosis. J Clin Invest 2004;114:438446.
  • 79
    Hashimoto N, Jin H, Liu T, Chensue SW, Phan SH. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 2004;113:243252.
  • 80
    Desmouliere A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995;146:5666.
  • 81
    Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002;3:349363.
  • 82
    Thannickal VJ, Toews GB, White ES, Lynch JP, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med 2004;55:395417.
  • 83
    Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:12861292.
  • 84
    Chapman HA. Disorders of lung matrix remodeling. J Clin Invest 2004;113:148157.
  • 85
    Horowitz JC, Lee DY, Waghray M, Keshamouni VG, Thomas PE, Zhang H et al. Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta 1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J Biol Chem 2004;279:13591367.
  • 86
    Zhang HY, Phan SH. Inhibition of myofibroblast apoptosis by transforming growth factor beta(1). Am J Respir Cell Mol Biol 1999;21:658665.
  • 87
    Sun G, Stacey MA, Bellini A, Marini M, Mattoli S. Endothelin-1 induces bronchial myofibroblast differentiation. Peptides 1997;18:14491451.
  • 88
    Bogatkevich GS, Tourkina E, Silver RM, Ludwicka-Bradley A. Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolitically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem 2001;276:4518445192.
  • 89
    Morishima Y, Nomura A, Uchida T, Noguchi Y, Sakamoto T, Ishii Y et al. Triggering the induction of myofibroblast and fibrogenesis by airway epithelial shedding. Am J Respir Cell Mol Biol 2001;24:111.
  • 90
    Gericke A, Munson M, Ross AH. Regulation of the PTEN phosphatase. Gene 2006;374:19.
  • 91
    Di Cristofaro A, Pesce B, Cordon-Cardo C, Pandolfi PP. PTEN is essential for embryonic development and tumour suppression. Nat Genet 1998;19:348355.
  • 92
    Stiles B, Groszer M, Wang S, Jiao J, Wu H. PTEN less means more. Dev Biol 2004;273:175184.
  • 93
    Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006;3:350356.
  • 94
    Lappi-Blanco E, Soini Y, Paakko P. Apoptotic activity is increate in the newly formed fibromyxoid connective tissue in bronchiolitis obliterans organizing pneumonia. Lung 1999;177:367376.
  • 95
    White ES, Atrasz RG, Hu B, Phan SH, Stambolic V, Mak TW et al. Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on Chromosome 10). Am J Respir Crit Care Med 2006;173:112121.
  • 96
    Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med 2006;203:28952906.
  • 97
    Verma S, Slutsky AS. Idiopathic pulmonary fibrosis – new insights. N Engl J Med 2007;356:13701372.
  • 98
    Schwencke C, Braun-Dullaeus RC, Wunderlich C, Strasser RH. Caveolae and caveolin in transmembrane signaling: implications for human disease. Cardiovasc Res 2006;70:4249.
  • 99
    Li H, Xu D, Li J, Berndt MC, Liu JP. Transforming growth factor beta suppresses human telomerase reverse transcriptase (hTERT) by Smad3 interactions with c-Myc and the hTERT gene. J Biol Chem 2006;281:2558825600.
  • 100
    Weitzenblum E, Ehrhart M, Rasaholinjanahary J, Hirth C. Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases. Respiration 1983;44:118127.
  • 101
    Leuchte HH, Neurohr C, Baumgartner R, Holzapfel M, Giehrl W, Vogeser M et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004;170:360365.
  • 102
    Weitzenblum E, Chaouat A. Pulmonary hypertension due to chronic hypoxic lung disease. In: PeacockAJ, RubinLJ, editors. Pulmonary circulation: diseases and their treatment. London: Arnold, 2004:374386.
  • 103
    Katzenstein AL. Idiopathic interstitial pneumonia. In: KatzensteinAL, editor. Katzenstein and Askin’s surgical pathology of non-neoplastic lung disease. Philadelphia: WB Saunders Co, 1997:4880.
  • 104
    Colombat M, Mal E, Groussard O, Capron F, Thabut G, Jebrak G et al. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Human Pathol 2007;38:6065.
  • 105
    Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006;129:746752.
  • 106
    Turner-Warwick M. Precapillary systemic-pulmonary anastomoses. Thorax 1963;18:225237.
  • 107
    Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 2004;59:581585.
  • 108
    Chambers RC. Abnormal wound healing responses in pulmonary fibrosis: focus on coagulation signalling. Eur Respir Rev 2008;17:130137.
  • 109
    Ambrosini V, Cancellieri A, Chilosi M, Zompatori M, Trisolini R, Saragoni L et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 2003;22:821826.
  • 110
    Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS ONE 2007;2:e482.
  • 111
    Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA et al. Idiopathic pulmonary fibrosis study group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Eng J Med 2004;350:125133.
  • 112
    Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 2005;128:33103315.
  • 113
    Rice AJ, Wells AU, Bouros D, Du Bois RM, Hansell DM, Polychronopoulos V et al. Terminal diffuse alveolar damage in relation to interstitial pneumonias: an autopsy study. Am J Clin Pathol 2003;119:709714.
  • 114
    Schwartz DA. The importance of gene-environment interactions and exposure assessment in understanding human diseases. J Expo Sci Environ Epidemiol 2006;16:474476.
  • 115
    Suga M, Iyonaga K, Okamodo T, Gushima Y, Miyakawa H, Akaike T et al. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2000;162:19491956.
  • 116
    Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 2003;28:1224.
  • 117
    Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000;14:163176.
  • 118
    Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005;128:14751482.
  • 119
    Tsakiri K, Cronkhite J, Kuan P, Xing C, Raghu G, Weissler JC et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007;104:75527557.
  • 120
    Xu D, Chan WL, Leung BP, Hunter D, Schulz K, Carter RW et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998;187:787794.
  • 121
    Tajima S, Oshikawa K, Tominaga S, Sugiyama Y. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 2003;124:12061214.
  • 122
    Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest 2007;132:16521658.
  • 123
    Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:10401047.
  • 124
    Homma S, Sakamoto S, Kawabata M, Kishi K, Tsuboi E, Motoi N et al. Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia. Intern Med 2005;44:11441150.
  • 125
    Noth I, Martinez FJ. Recent advances in idiopathic pulmonary fibrosis. Chest 2007;132:637650.
  • 126
    Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 2007;30:835839.
  • 127
    American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277304.
  • 128
    Nicholson AG, Wells AU. Nonspecific interstitial pneumonia – nobody said it’s perfect. Am J Respir Crit Care Med 2001;164:15531554.
  • 129
    Latsi PI, Du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531537.
  • 130
    Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB, Colby TV et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003;58:143148.
  • 131
    Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006;27:143150.
  • 132
    Yang IV, Burch LH, Steele MP, Savov JD, Hollingsworth JW, McElvania-Tekippe E et al. Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med 2007;175:4554.
  • 133
    Teirstein AS. The elusive goal of therapy for usual interstitial pneumonia. N Eng J Med 2004;350:181183.
  • 134
    Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003;3:CD003134.
  • 135
    Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:15481561.
  • 136
    Raghu G, Brown KK, Cottin V, Du Bois RM, Lasky JA et al. Treatment of idiopathic pulmonary fibrosis with etanercept. An exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008;178:948955.
  • 137
    Jackson RM, Fell CD. Etanercept for idiopathic pulmonary fibrosis. Lessons on clinical trial design. Am J Respir Crit Care Med 2008;178:889893.
  • 138
    King TE Jr, Behr J, Brown KK, Du Bois RM, Lancaster L, De Andrade JA et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:7581.
  • 139
    Shi-Wen X, Denton CP, Dashwood ME, Holmes AM, Bou-Gharios G, Pearson JD et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001;116:417425.
  • 140
    Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989;139:370372.
  • 141
    Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:22292242.
  • 142
    Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007;131:897899.
  • 143
    Bouros D, Antoniou KM. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 2005;26:693702.
  • 144
    Benito M, Diaz-Rubio E. Molecular biology in colorectal cancer. Clin Transl Oncol 2006;8:391398.
  • 145
    Lawson WE, Lloyd JE. The genetic approach in pulmonary fibrosis: can it provide clues to this complex disease? Proc Am Thorac Soc 2006;3:345349.
  • 146
    Vassilakis DA, Sourvinos G, Spandidos DA, Siafakas NM, Bouros D. Frequent genetic alterations at the microsatellite level in cytologic sputum samples of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2000;162:11151119.
  • 147
    Chambers RC. Role of coagulation cascade proteases in lung repair and fibrosis. Eur Respir J 2003;22:33S35S.